By Dr. Anish Shah Bronx-Lebanon Hospital On August 14, 2023, the U.S. Food and Drug Administration approved HEPZATO KIT – which is melphalan, as a liver-directed treatment for adult patients with
Author: Saramshika Dhakal, MBBS Tribhuvan University Teaching Hospital, Kathmandu, Nepal. In a recent article published in JAMA Oncology (JAMA Oncol. 2023;9(4):465-472; researcher Simiao Chen and the team have estimated that the
More
By Akshat Jain MD, MPH Hematology Oncology and Cellular Therapy Faculty Department of Pediatrics & Clinical Medicine Loma Linda University School of Medicine Loma Linda University Children’s Hospital Assistant Professor of Public
More
By Dr. Anish Shah Bronx-Lebanon Hospital On August 14, 2023, the U.S. Food and Drug Administration approved HEPZATO KIT – which is melphalan, as a liver-directed treatment for adult patients with
More
By Dr. Anish Shah Bronx-Lebanon Hospital On August 14, 2023, the U.S. Food and Drug Administration granted accelerated approval to Elranatamab-bcmm (Elrexfio) for adults with relapsed or refractory multiple myeloma who
More
Palbociclib after progression on Palbociclib in HR-positive HER2-negative breast cancer does not show improvement in progression-free survival By Dr. Malak Alharbi of Roswell Park Comprehensive Cancer Center CDK4/6i plus endocrine
More